These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8578859)

  • 1. The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses.
    Laviada MD; Roy P; Sánchez-Vizcaíno JM; Casal JI
    Virus Res; 1995 Oct; 38(2-3):205-18. PubMed ID: 8578859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of the immunoenzyme test ELISA-NS3 to distinguish horses infected by African horsesickness virus from vaccinated horses].
    Idrissi Bougrine S; Fassi Fihri O; el Harrak M; Fassi Fehri MM
    Rev Sci Tech; 1999 Dec; 18(3):618-26. PubMed ID: 10588005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
    van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
    Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of African horse sickness virus VP7 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA.
    Wade-Evans AM; Woolhouse T; O'Hara R; Hamblin C
    J Virol Methods; 1993 Dec; 45(2):179-88. PubMed ID: 8113344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Western immunoblotting as a method for the detection of African horse sickness virus protein-specific antibodies: differentiation between infected and vaccinated horses.
    Bougrine SI; Fihri OF; Fehri MM
    Arch Virol Suppl; 1998; 14():329-36. PubMed ID: 9785518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera.
    Maree S; Paweska JT
    J Virol Methods; 2005 Apr; 125(1):55-65. PubMed ID: 15737417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Luminex-Based DIVA Assay for Serological Detection of African Horse Sickness Virus in Horses.
    Sánchez-Matamoros A; Nieto-Pelegrín E; Beck C; Rivera-Arroyo B; Lecollinet S; Sailleau C; Zientara S; Sánchez-Vizcaíno JM
    Transbound Emerg Dis; 2016 Aug; 63(4):353-9. PubMed ID: 27090377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.
    Faber FE; van Kleef M; Tshilwane SI; Pretorius A
    Virus Res; 2016 Jul; 220():12-20. PubMed ID: 27063332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of reverse transcriptase-polymerase chain reaction (RT-PCR) and dot-blot hybridisation for the detection and identification of African horse sickness virus nucleic acids.
    Zientara S; Sailleau C; Moulay S; Crucière C; el-Harrak M; Laegreid WW; Hamblin C
    Arch Virol Suppl; 1998; 14():317-27. PubMed ID: 9785517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of nonstructural protein NS3 of African horsesickness virus (AHSV): evidence for a cytotoxic effect of NS3 in insect cells, and characterization of the gene products in AHSV infected Vero cells.
    van Staden V; Stoltz MA; Huismans H
    Arch Virol; 1995; 140(2):289-306. PubMed ID: 7710356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization.
    Martinez-Torrecuadrada JL; Iwata H; Venteo A; Casal I; Roy P
    Virology; 1994 Jul; 202(1):348-59. PubMed ID: 8009847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological and virological responses in mules and donkeys following inoculation with African horse sickness virus serotype 4.
    el Hasnaoui H; el Harrak M; Zientara S; Laviada M; Hamblin C
    Arch Virol Suppl; 1998; 14():29-36. PubMed ID: 9785493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
    de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
    PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
    Crafford JE; Lourens CW; Gardner IA; Maclachlan NJ; Guthrie AJ
    Equine Vet J; 2013 Sep; 45(5):604-7. PubMed ID: 23294121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.
    Mathebula EM; Faber FE; Van Wyngaardt W; Van Schalkwyk A; Pretorius A; Fehrsen J
    Onderstepoort J Vet Res; 2017 Feb; 84(1):e1-e12. PubMed ID: 28281773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.